Loading…
TNYA
Tenaya Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 87990A106
$0.68+1.25%Price as of Sep 22, 22:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $152.97M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.51
- ROE
- -121.86%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.78
- 52-week high
- $2.35
- 52-week low
- $0.53
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -97.6% over 5Y.
today you would have $29.52▼ -97.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $0.71 | $1.43 | $3.24 | $2.01 | $18.95 | |
| P/B | 1.3x | 1.3x | 1.3x | 1.8x | 0.6x | 2.8x |
| EPS | -$0.59 | -$1.31 | -$1.68 | -$2.76 | -$4.10 | |
| ROE | -73.50% | -73.50% | -119.68% | -89.00% | -50.81% | -26.11% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OKUROnKure Therapeutics, Inc. | $3.79 | — | 0.9x | — | -46.91% | $153.48M |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | $7.88 | — | 1.4x | — | -95.58% | $152.31M |
| KRROKorro Bio, Inc. | $10.34 | — | 1.5x | — | -97.69% | $152.26M |
| NRXPNRX Pharmaceuticals, Inc. | $3.55 |
About the company
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
- 70
- South San Francisco, United States
Company description provided by Yahoo Finance.